Holen Sie sich die Stockscreener-App
0.2999
11.66%
-0.0396
Handel nachbörslich:
.29
-0.0099
-3.30%
Schlusskurs vom Vortag:
$0.3395
Offen:
$0.33
24-Stunden-Volumen:
780.47K
Relative Volume:
0.89
Marktkapitalisierung:
$17.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.1158
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-23.61%
1M Leistung:
-1.64%
6M Leistung:
-87.24%
1J Leistung:
-91.89%
1-Tages-Spanne:
$0.2955
$0.3395
1-Wochen-Bereich:
$0.283
$0.38
52-Wochen-Spanne:
$0.2806
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.2999 | 17.51M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright - Defense World
BioAtla (NASDAQ:BCAB) Given “Neutral” Rating at HC Wainwright - Defense World
BioAtla stock price target cut to $1 by Citizens JMP - Investing.com Australia
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
BioAtla price target lowered to $1 from $5 at Citizens JMP - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript - MSN
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook - TipRanks
BioAtla stock price target cut to $10 at BTIG, retains Buy rating - Investing.com Canada
BioAtla stock price target cut to $10 at BTIG, retains Buy rating By Investing.com - Investing.com South Africa
BioAtla Inc. (BCAB) reports earnings - Quartz
BioAtla, Inc. SEC 10-K Report - TradingView
BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises - Investing.com India
BioAtla announces restructuring, to cut over 30% of workforce - TipRanks
BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year - TipRanks
Bioatla IncAnnounces 30% Workforce Reduction - MarketScreener
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - The Manila Times
Earnings Outlook For BioAtla - Benzinga
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - Quantisnow
BioAtla, Inc. Announces Abstract Presentations at European Lung Cancer Congress and Mayo Clinic Symposium 2025 - Nasdaq
BioAtla Advances Cancer Research with Dual Presentations at Elite European and Mayo Clinic Conferences - Stock Titan
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - Quantisnow
BioAtla Earnings Alert: Key Q4 and 2024 Results Coming March 27What to Watch - Stock Titan
BioAtla (BCAB) Expected to Announce Quarterly Earnings on Tuesday - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
BioAtla Awards Executive Bonuses and Stock Units - TipRanks
What Are You Thinking About Investing In BioAtla Inc (NASDAQ: BCAB) Stock? - stocksregister.com
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 12.6% in February - Defense World
Bioatla stock hits 52-week low at $0.38 amid sharp decline By Investing.com - Investing.com South Africa
Bioatla stock hits 52-week low at $0.38 amid sharp decline - Investing.com UK
BioAtla Inc (BCAB) shows promising results - US Post News
Market Momentum Report: BioAtla Inc (BCAB)’s Negative Close at 0.45 - The Dwinnex
BioAtla Inc: Navigating a Turbulent Year, Up -88.84% from 52-Week Low - The InvestChronicle
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla Inc (BCAB) Shares Down Despite Recent Market Volatility - The News Heater
Millennium Management LLC Reduces Stake in BioAtla Inc. - GuruFocus.com
Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – Here’s Why - Defense World
Bioatla stock hits 52-week low at $0.57 amid sharp decline - Investing.com
Fierce Biotech Layoff Tracker 2025: BioAtla implements 30% RIF; Nkarta cuts 53 roles - Fierce Biotech
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):